CARIOUS EFFECTS OF DRUG INDUCED XEROSTOMIA (CEDIX)

描述：(摘自摘要)：本研究的重点是干旱体 处方药的效果和后果。这个项目是一个 以人群为基础的回溯性队列研究，以确定和定义 药物引起的口干症与龋齿之间的关联程度 55岁以上的成年人是两个大型医疗保健组织之一的成员：Kaiser Permanente 西北分区(波特兰或)和HealthPartners(明尼阿波利斯/圣保罗) 研究是纵向的，将确定剂量水平和发作 药物使用、拔牙率、修复性牙科护理和费用 与干燥的药物有关。 (第27-8页)：队列包括所有55岁的牙科计划成员 或在1998年12月31日或以上，有资格获得医疗和牙科护理，并有 9月11日至98年12月31日期间的药房福利 自1990年1月1日起服用药物，并在治疗期间至少看过一次牙 句号。这项研究分析的数据将主要来自计算机- 为KPNW和HP的计划成员生成管理文件。数据库 将通过审查患者记录来补充和核实信息 以及对成员的抽样调查问卷。这项调查将确定 与口干症和风险增加相关的其他因素的信息 龋齿和牙齿脱落的风险，包括吸烟和饮酒，液体摄入， 咖啡因的使用，以及非处方药。口干症的程度不会是 通过临床检查进行量化。对于已知的每一种药物的分配 与口干症有关，药物治疗的一个插曲将是 已创建。使用以前与口干症无关的药物将 也被跟踪，以确定新的关联。对于每个科目，一个 将创建药物使用配置文件，并将此配置文件与 牙科使用率(服务类型和数量以及费用) 评估过了。 调查人员估计，他们的研究队列将包括远远超过 10万人。

DESCRIPTION: (from the abstract): The focus of this study is the xerostomic effects and consequences of prescription medications. The project is a population-based, retrospective cohort study to determine and define the magnitude of the association between drug-induced xerostomia and dental caries in adults over 55 who are members of one of two large HMOs: Kaiser Permanente Northwest Division (Portland OR) and HealthPartners (Minneapolis/St Paul) The study is longitudinal and will ascertain dosage levels and episodes of medication use, and rates of extractions, restorative dental care, and costs associated with xerostomic medications. (From pg 27-8): The cohort includes all dental plan members who were 55 years or older on 12/31/98, who were eligible for medical and dental care and had a pharmacy benefit between 11/90 to 12/31/98, who were not taking any medications as of 1/1/90, and who had at least one dental visit during the period. The data analyzed for the study will be derived mostly from computer- generated administrative files for plan members of KPNW and HP. The database information will be supplemented and verified by a review of patient records as well as a questionnaire of a sample of members. The survey will ascertain information on other factors associated with xerostomia and an increased risk of caries and tooth loss, including tobacco and alcohol use, fluid intake, caffeine use, and OTC medications. The extent of xerostomia will not be quantified through clinical examinations. For each dispensing of a drug known to be associated with xerostomia, an episode of drug therapy will be created. Use of medications not previously associated with xerostomia will also be tracked, in order to determine new associations. For each subject, a drug use profile will be created, and associations between this profile and dental utilization (type and number of services as well as cost) will be assessed. The investigators estimate that their study cohort will include well over 100,000 people.